HIMR BLAINE, Wash., April 17, 2013 /PRNewswire/ -- Hollund Industrial Marine, Inc. (PINKSHEETS: HIMR) ("Hollund" or the "Company") announced today that on the evening of April 15th, 2013, the Company made a voluntary filing of its Annual Report with OTC Markets; while looking to begin the auditing process within the 3rd QT of this year. "This filing was unlike any other for us," stated Peter Meier, President of Hollund. "While we are generally timely with our filings, given our current ambition, we thought it appropriate to take a bit more care and diligence to help ensure an easier transition from 'voluntary' filings to 'SEC required' filings." As mentioned in October 2012, the company sought to eventually obtain a PCAOB audit and file with the SEC. According to management, the company still intends to pursue 'up-listing' within the year, should certain key opportunities come to fruition. Mr. Meier continued, "February was initially considered to be our transitioning period to the PCAOB audit. However, this past filing was an eye opener to our true potential. Today we feel much more prepared to formally commence the up-listing process sometime within the third quarter of the year. We expect this event to be proceeded by two major accomplishments." Management has indicated that its South American Project Development Team has made considerable strides in securing concessions in Latin America. With concessions "come financing opportunities," said Meier. Meier concluded, "Should the preliminary study of the targeted asset prove positive, we believe that funding will shortly follow. Should this be the case, then our up-listing will be accompanied by considerable opportunity and value for our shareholders."
HIMR BLAINE, Wash., April 17, 2013 /PRNewswire/ -- Hollund
Top 10 Most Recent News Articles
Sitting, Lymph Flow, and a Supplement Maker's Pitch
By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...
Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era
A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...
Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint
A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...
Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims
Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...
Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut
Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...
Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle
A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...
Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis
A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...
Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock
August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...
Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure
Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...
Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look
Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...
Continue Reading